Similar articles for PMID: 16000280

Year	Number of Results
1985	1
1986	1
1994	2
1996	3
1997	6
1998	9
1999	6
2000	7
2001	2
2002	6
2003	10
2004	17
2005	13
2006	11
2007	9
2008	6
2009	3
2010	6
2011	8
2012	10
2013	6
2014	3
2015	5
2016	3
2017	3
2018	2
2019	1
2020	1
2022	1
2023	1
2024	0

1

Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion.

Pinborg LH, Ziebell M, Frøkjaer VG, de Nijs R, Svarer C, Haugbøl S, Yndgaard S, Knudsen GM. Pinborg LH, et al. J Nucl Med. 2005 Jul;46(7):1119-27. J Nucl Med. 2005. PMID: 16000280 Free article. Clinical Trial.

2

Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.

Prunier C, Payoux P, Guilloteau D, Chalon S, Giraudeau B, Majorel C, Tafani M, Bezard E, Esquerré JP, Baulieu JL. Prunier C, et al. J Nucl Med. 2003 May;44(5):663-70. J Nucl Med. 2003. PMID: 12732666 Free article.

3

Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I.

Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, Knudsen GM. Ziebell M, et al. J Nucl Med. 2010 Dec;51(12):1885-91. doi: 10.2967/jnumed.110.078337. Epub 2010 Nov 15. J Nucl Med. 2010. PMID: 21078806 Free article. Clinical Trial.

4

Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT.

Ziebell M. Ziebell M. Dan Med Bull. 2011 May;58(5):B4279. Dan Med Bull. 2011. PMID: 21535991 Free article. Review.

5

[(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain.

Halldin C, Erixon-Lindroth N, Pauli S, Chou YH, Okubo Y, Karlsson P, Lundkvist C, Olsson H, Guilloteau D, Emond P, Farde L. Halldin C, et al. Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1220-30. doi: 10.1007/s00259-003-1212-3. Epub 2003 Jun 13. Eur J Nucl Med Mol Imaging. 2003. PMID: 12811422

6

Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.

Sasaki T, Ito H, Kimura Y, Arakawa R, Takano H, Seki C, Kodaka F, Fujie S, Takahata K, Nogami T, Suzuki M, Fujiwara H, Takahashi H, Nakao R, Fukumura T, Varrone A, Halldin C, Nishikawa T, Suhara T. Sasaki T, et al. J Nucl Med. 2012 Jul;53(7):1065-73. doi: 10.2967/jnumed.111.101626. Epub 2012 Jun 11. J Nucl Med. 2012. PMID: 22689927 Free article.

7

Quantification of [(123)I]PE2I binding to dopamine transporters with SPET.

Pinborg LH, Videbaek C, Svarer C, Yndgaard S, Paulson OB, Knudsen GM. Pinborg LH, et al. Eur J Nucl Med Mol Imaging. 2002 May;29(5):623-31. doi: 10.1007/s00259-001-0742-9. Epub 2002 Mar 1. Eur J Nucl Med Mol Imaging. 2002. PMID: 11976800 Clinical Trial.

8

Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline.

Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Schwarz J, et al. J Nucl Med. 2004 Oct;45(10):1694-7. J Nucl Med. 2004. PMID: 15471835 Free article. Clinical Trial.

9

Comparison of 4 methods for quantification of dopamine transporters by SPECT with [123I]IACFT.

Bonab AA, Fischman AJ, Alpert NM. Bonab AA, et al. J Nucl Med. 2000 Jun;41(6):1086-92. J Nucl Med. 2000. PMID: 10855640 Free article.

10

Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT.

Ziebell M, Thomsen G, Knudsen GM, de Nijs R, Svarer C, Wagner A, Pinborg LH. Ziebell M, et al. Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):101-9. doi: 10.1007/s00259-006-0161-z. Epub 2006 Jul 29. Eur J Nucl Med Mol Imaging. 2007. PMID: 16896668

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

148 results

Results by year